In an effort to lower the price of a leading artemisinin based combination therapy (ACT) for malaria by 30 per cent and reduce the price volatility of artemisinin, the key raw material for this and other ACTs by 70 per cent, the Mumbai-based Calyx Chemicals and Pharmaceuticals Ltd, has joined hands with Clinton Foundation, which together with the UN Special Envoy on malaria is working on the same objective. With this agreement, Calyx has extended its product range into malaria. The collaboration is part of Clinton Foundation's recent agreement with six companies for the purpose.

As per the agreement, the company would supply artemisinin derivatives at a price which will make the effective malaria treatment affordable and accessible to various countries in Africa, Asia, Latin America and the Caribbean that make up the Clinton HIV/AIDS Initiative (CHAI) purchasing consortium.

"We are proud to work with the Clinton Foundation. This is our first partnership with a non-governmental organisation and one thing that strikes me about our work to-date is the Clinton Foundation's ability to understand how we as business people think. We are sure that our partnership with the Foundation would help us to better serve as many patients as possible," said Smitesh Shah, chairman and managing director, Calyx.


Calyx currently service leading drug discovery companies around the world with their requirements for contract manufacturing, custom synthesis and collaborative research and development (R&D). Calyx offers a range of APIs, chemical intermediates and building blocks to pharmaceuticals, biotech, chemical and drug discovery companies.

Also, the company aims at innovation in R&D and excellence in various processes. The company is fully focused on developing its R&D facility as per the international standards and for that matter it has set up a state-of-the-art research facility duly approved by Department of Scientific & Industrial Research, India.

Apart from the new R&D facility in Mumbai, Calyx has multipurpose manufacturing plants that comply with cGMP, US FDA, WHO and EDQM. The company has marketing and sales offices in US and Japan, apart from a sourcing office in China. In the past few years, Calyx has entered into agreements with 3 of the top 10 pharma companies across the world and has become an integral part of their supply chain.